Why did Gilead Sciences (GILD) stock move recently?

On 8/4/2026, Gilead Sciences moved +3.1% — Gilead shares rose ahead of its Q2 2026 earnings release (after close) on positive resolution of litigation overhang, as the California Supreme Court ruled in the company's favor Aug 3 in the TDF 'duty to innovate' case and dismissed claims. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Gilead Sciences (GILD) overvalued or fairly valued?

MarketChacha shows Gilead Sciences's valuation in context — a forward P/E of about 15.7, a price-to-book of about 16.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Gilead Sciences's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.97×) from reported figures — education, not a rating.

What is Gilead Sciences's revenue?

Gilead Sciences reported revenue of $29.4B for FY2025, with net profit of $8.5B, per official filings.

What is the share price of Gilead Sciences (GILD)?

Gilead Sciences last traded at $156.19 (-0.7% on the day), as of 10/16/2026 — a delayed quote shown for education, not investment advice.

Gilead Sciences

GILD · NASDAQ · Biotech · United States

Snapshot

TickerGILD

ExchangeNASDAQ

SectorBiotech

IndustryDrug Manufacturers - General

CountryUnited States

Employees17,000

HeadquartersFoster City, United States

Websitewww.gilead.com

Filings tracked18

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Who owns it

Insiders0.1%
Institutions92.1%
Public & other7.8%

3,096 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.83%
Vanguard Capital Management LLC6.54%
FMR, LLC5.39%
State Street Corporation4.94%
Capital World Investors3.31%
Invesco Ltd.3.21%
Vanguard Portfolio Management LLC2.85%
Geode Capital Management, LLC2.42%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.97×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend20.9% → 28.9%

Margin has expanded by about 8.0 points — the business is getting more profitable.

Return on equity37.5%

Latest ROE of 37.5% — capital is generating a healthy return.

Growth qualityrev 4% · PAT 23%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $8.1B · EPS 2.17

Est. earnings growth +16.5%

Next fiscal year

Rev $32.8B · EPS 9.94

Est. earnings growth +2586.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$29.4B

Net margin

28.9%

ROE

37.5%

Revenue CAGR (2y)

+4.2%

Profit CAGR (2y)

+22.6%

EPS (FY2025)

6.78

Net profit (FY2025)

$8.5B

Ask MarketChacha about GILD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Gilead shares rose ahead of its Q2 2026 earnings release (after close) on positive resolution of litigation overhang, as the California Supreme Court ruled in the company's favor Aug 3 in the TDF 'duty to innovate' case and dismissed claims.
source 1 ↗source 2 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$29.4B	$8.5B	6.78	28.9%	37.5%
FY2024	$28.8B	$480.0M	0.38	1.7%	2.5%
FY2023	$27.1B	$5.7B	4.50	20.9%	24.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$7.8B	$-10.5B	-8.45	-134.5%
2026Q1	$7.0B	$2.0B	1.61	29.0%
2025Q3	$7.8B	$3.1B	2.43	39.3%
2025Q2	$7.1B	$2.0B	1.56	27.7%
2025Q1	$6.7B	$1.3B	1.04	19.7%
2024Q3	$7.5B	$1.3B	1.00	16.6%
2024Q2	$7.0B	$1.6B	1.29	23.2%
2024Q1	$6.7B	$-4.2B	-3.34	-62.4%
2023Q3	$7.1B	$2.2B	1.73	30.9%
2023Q2	$6.6B	$1.0B	0.83	15.8%
2023Q1	$6.4B	$1.0B	0.80	15.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q — FORM 10-Q
SEC8/6/2026
8-K — Results of operations, Exhibits
SEC8/4/2026material
8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC5/20/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q — FORM 10-Q
SEC5/7/2026
8-K — Shareholder vote results, Exhibits
SEC5/4/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC4/28/2026material
10-K — FORM 10-K
SEC2/24/2026
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC2/23/2026material
8-K — Results of operations, Exhibits
SEC2/10/2026material

2025

8-K — Executive/director change
SEC11/19/2025material
10-Q — FORM 10-Q
SEC11/7/2025
8-K — Results of operations, Exhibits
SEC10/30/2025material
8-K — Reg FD disclosure, Exhibits
SEC10/6/2025material
8-K — Executive/director change
SEC8/14/2025material
8-K — Results of operations, Exhibits
SEC8/7/2025material
10-Q — FORM 10-Q
SEC8/7/2025
8-K — Bylaw/charter change, Exhibits
SEC8/4/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.